Literature DB >> 3594485

In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line.

G J Pommier, F L Garrouste, D Bettetini, J M Culouscou, M M Remacle-Bonnet.   

Abstract

Products secreted by HT-29 human colonic adenocarcinoma cells (DMEM-HT-29) mediated strong suppressive activity of in vitro lymphoproliferative responses to several mitogens. In vivo administration of DMEM-HT-29 both inhibited the afferent limb of delayed-type hypersensitivity against the Mc FiFi2(s) syngeneic fibrosarcoma and delayed the rejection of these tumor cells by immunized animals. Transfer experiments prior or after cell fractionation did not demonstrate suppressor cells induced by DMEM-HT-29. This suggests that DMEM-HT-29 produces its effect by directly interacting with macrophage and/or T cells at the sensitization stage of the antitumor immune response.

Entities:  

Mesh：

Year:  1987        PMID： 3594485     DOI： 10.1007/bf00205634

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  38 in total

Review 1.  Polyamines in rapid growth and cancer.

Authors:  J Jänne; H Pösö; A Raina
Journal:  Biochim Biophys Acta       Date:  1978-04-06

2.  Inhibition of lymphocyte growth by spermidine in medium containing fetal bovine serum.

Authors:  T L Swanson; G E Gibbs
Journal:  In Vitro       Date:  1980-09

Review 3.  Polyamines in mammalian tumors. Part II.

Authors:  G Scalabrino; M E Ferioli
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

4.  Enhancement of production of superoxide anion by human monocytes exposed to products of HT 29 human colonic adenocarcinoma cell line.

Authors:  D Bettetini; F Garrouste; M Remacle-Bonnet; J M Culouscou; J Marvaldi; G Pommier
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

5.  Modulation of anti-tumour immunity induced by syngeneic mitomycin C-treated murine tumour cells.

Authors:  R Kearney; P Harrop
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

6.  Immunomodulating activities associated with the cytosol fraction of a 3-methylcholanthrene-induced rat fibrosarcoma.

Authors:  M P San Marco; G J Pommier; M C Chabrol; D H Adda; R C Depieds
Journal:  J Natl Cancer Inst       Date:  1984-05       Impact factor: 13.506

7.  Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.

Authors:  M Rosenstein; T J Eberlein; S A Rosenberg
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.

Authors:  P D Greenberg
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

9.  The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.

Authors:  D Taramelli; G Fossati; A Balsari; R Marolda; G Parmiani
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

10.  Purification and functional characterization of a low molecular weight immune modulating factor produced by Lewis lung carcinoma.

Authors:  M R Young; G Sundharadas; W D Cantarow; P R Kumar
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396
View more
  2 in total

1.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.

Authors:  P J Guillou; C W Ramsden; S S Somers; P C Sedman
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.